New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.

US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.

Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label. 

Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.